(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Trump says Cuba is 'ready to fall' after capture of Venezuela's Maduro - 2The most effective method to Pick A Trade-in vehicle Stage
- 3We analyzed Philly street scenes and identified signs of gentrification using machine learning trained on longtime residents’ observations
- 4It's been 20 years since MTV's golden couple split. These producers saw it all unravel.
- 5Elite Execution Gaming PCs for Gamers
- Reactions as Artemis II astronauts lift off on historic lunar mission
- Extraordinary Shows to Long distance race on a Plane
- Mosquitoes carrying malaria are evolving more quickly than insecticides can kill them – researchers pinpoint how
- Most normal matter in the universe isn't found in planets, stars or galaxies – an astronomer explains where it's distributed
- Instructions to Decide the Best SUV Size for Seniors
- Mississippi Insight for Jan. 11, 2026
- CDC's upcoming vote on hepatitis B vaccine could impact childhood immunization
- A definitive Manual for 2024's Most In vogue Wedding Dresses
- Most loved Road Food: Which One Prevails upon You?
